Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarker Type (Functional Biomarker, Up-regulated Protein, Other Biomarker Types), By Diagnostic Technique (Enzyme-linked Immunosorbent Assay, Colorimetric Assay, Particle-enhanced Turbidimetric Immunoassay (PETIA), Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass, Spectrometry (LC-MS)), By End-User (Hospital, Diagnostic Laboratory, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Renal Biomarkers Market Size

The global renal biomarkers market size was valued at USD 1.61 billion in 2025 and is projected to grow from USD 1.73 billion in 2026 to USD 3.01 billion by 2034, registering a CAGR of 7.19% during the forecast period from 2026 to 2034. North America dominated the renal biomarkers market with a market share of 38.4% in 2025.

Biomarkers are substances that can be measured objectively and analyzed to determine whether a patient's kidney function is normal or abnormal. Biomarkers can also evaluate pathogenic processes or pharmacological responses to therapeutic interventions. Therefore, they are essential to the identification and prognosis of acute kidney injury (AKI) and chronic kidney disease (CKD).

Biomarkers can be cells found on a urinalysis, proteins, microRNAs, genes, lipids, metabolites, or proteomic patterns. In the case of CKD, in particular, biomarkers are typically those that can be used to assess the kidney's glomerular filtration rate (GFR). This decline denotes a decline in renal function. GFR measurement is essential for CKD diagnosis, illness monitoring, and drug dosage determination. The main indicators to calculate GFR include blood urea nitrogen (BUN), urine albumin/protein, serum creatinine (SCr), and volume excretion.

Biomarker Type Insights

The functional biomarker segment dominates the global market and is anticipated to grow at a CAGR of 7.35% over the forecast period. The functional biomarker segments are further sub-segmented into serum creatinine, serum cystatin C, and urine albumin. Serum creatinine is the most widely used laboratory test for kidney function and is used to derive the eGFR (estimated Glomerular Filtration Rate) as an indicator of kidney function. It is also used as an ideal indicator for determination of chronic kidney diseases. In addition, Cystatin is a protein produced in the body by the cells. Cystatin C concentration in the blood is entirely dependent on kidney function. Albumin is synthesized in the parenchymal cells of the body. The blood plasma, cerebrospinal fluid (CSF), and urine have around 50% albumin in the body. The urine albumin segment is driven by the availability of these biomarkers through major companies across the market.

The up-regulated protein segment is further sub-segmented into neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and interleukin 18. NGAL (Neutrophil Gelatinase Associated Lipocalin) is a novel biomarker to diagnose acute renal injury (AKI) early. Kidney injury molecule-1 (T-cell immunoglobulin; mucin-containing molecule) is a type 1 transmembrane protein. KIM-1 is up-regulated in the kidney's dedifferentiated proximal tubule epithelial cells after ischemic or toxic injury. Interleukin 18 (IL-18) is an 18kDa novel cytokine identified as a co-stimulatory factor for producing interferon-γ (IFN- γ) in response to toxic shock. The precursor 24kDa molecule of IL-18, which lacks a signal peptide and needs to be broken down to form an active molecule, is produced during IL-18 synthesis.

Request Customizationto receive a tailored report.

Diagnostic Technique Insights

The global renal biomarkers market is bifurcated into enzyme-linked immunosorbent assay, colorimetric assay, particle-enhanced turbidimetric immunoassay (PETIA), chemiluminescent enzyme immunoassay (CLIA), and liquid chromatography-mass spectrometry (LS-MS).

The enzyme-linked immunosorbent assay segment owns the highest market share and is predicted to exhibit a CAGR of 7.19% over the forecast period. ELISA tests can be done quickly and are easy to carry out since they are designed to handle many samples in parallel rapidly. They represent a very popular choice for evaluating various research and diagnostic targets. The diagnostic kit DNlite-IVD103 has received the CE IVD mark and is authorized for sale in the European Union, according to a July 2020 announcement from Taiwan's Bio Preventive Medicine Corporation (BPM), a cutting-edge in-vitro diagnostic (IVD) firm. The "DNlite-IVD103" diagnostic test for stopping the progression of diabetic kidney disease is the first ELISA (Enzyme-linked Immunosorbent Assay) diagnostic kit to be made available globally.

Measuring a compound's concentration in a solution using a coloring agent is known as a colorimetric test. The colorimetric assay method is widely used in diagnostic laboratories and hospitals to diagnose different diseases. Due to their wide availability, there is a rapid growth in the number of improved colorimetric assay techniques for measuring protein concentrations to detect kidney diseases.

End-User Insights

The diagnostic laboratories segment is the most significant contributor to the market and is anticipated to exhibit a CAGR of 8.21% over the forecast period. The increasing prevalence of kidney diseases, initiatives by the government, and strategies undertaken by the major market players are the major factors fueling the increase in diagnostics laboratories, thereby increasing the tests performed in these diagnostic laboratories. With the automation and growing emergence of robotics in diagnostic laboratories, a transformation has increased productivity and lowered the cost of tests. Furthermore, the market of renal biomarkers usage in laboratories is expected to increase due to the collaboration between the manufacturers and laboratories to produce innovative products.

Hospitals play a vital role in renal diagnosis tests, as most patients visit hospitals due to kidney disorders. The startup cost is not prohibitive for most hospitals, given diagnostics' important clinical and financial benefits. Hence, most large-scale and middle-scale hospitals have inbuilt laboratories to diagnose kidney diseases. The major advantage of the diagnosis within the hospitals is that the results are easily accessible to the healthcare professionals to make the required decision.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global renal biomarkers market shareholder and is estimated to exhibit a CAGR of 7.74% during the forecast period. The U.S. has the largest market share in North America. The number of medicine labels, including molecular biomarker information approved by the US FDA, has significantly increased during the last ten years. Almost all pharmaceutical companies work on molecular biomarker studies, either independently or in collaboration with other businesses. The rising incidence of chronic kidney disease among Americans is one of the primary drivers behind the increased usage of renal biomarkers for accurate diagnosis and to propel the market expansion in this field. For example, the Centers for Disease Control and Prevention (CDC) anticipated that almost 37 million people in the United States more than 1 in 7 people have chronic renal disease in 2021. (CKD). Furthermore, the aging population in the United States is more susceptible to chronic kidney illnesses, fueling an increase in demand for early-stage diagnosis and efficient treatment, helping the market expand.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Renal Biomarkers Market Trends

Europe is predicted to grow at a CAGR of 7.16% over the forecast period. Germany dominates the European regional market. According to a study titled "Costs of patients with chronic kidney disease in Germany" that will be published in Plos One in April 2020, the prevalence of CKD in the adult German population is projected to range between 2% and 7%. The high prevalence of CKD in the German population will lead to increased adoption of renal biomarker tests, thereby driving the growth of this market in Germany. Furthermore, rising product launches demonstrating the effectiveness of kidney biomarker tests in the renal biomarkers market by the German players will lead to increased adoption of these tests, thereby driving market growth in Germany. For instance, in August 2020, SphingoTec GmbH, a diagnostics firm, released preliminary data demonstrating that their real-time kidney function biomarker penKid is a reliable biomarker for the diagnosis of Acute Kidney Infection in babies.

Asia-Pacific is predicted to grow considerably over the forecast period. In this region, China held the greatest market share. The market for renal biomarkers in China is estimated to be driven by a few factors, including a surge in the frequency of kidney illness, an increase in the testing of biomarkers for chronic kidney disease, and an increase in hypertension. According to the study published in BMC Nephrology in April 2020, the overall adjusted prevalence of Chronic Kidney Disease (CKD) was 16.8%, the prevalence of Diabetic Kidney Disease (DKD) was 3.5%, and in persons with diabetes, the total prevalence of CKD was 48%. The rising prevalence of CKD and DKD will also lead to increased adoption of renal biomarker testing in China, thereby driving the market's growth.

In the Middle East and Africa, factors such as the rising prevalence of kidney disease in these countries and the rising prevalence of diabetes, among others, are expected to propel the expansion of the renal biomarkers market. For example, according to the report published in the Saudi Journal of Kidney Diseases and Transplantation, titled 'Renal Data from the Arab World Dialysis in Kuwait: 2013-2019' in August 2020, in Kuwait, the total number of end-stage renal disease patients receiving dialysis in 2019 was 2230, up 6% over the previous year. In addition, the dialysis prevalence was 465 per million people, while dialysis incidence was 100 per million. Moreover, according to the International Diabetes Federation 2021, the total adult population in South Africa living with diabetes is 4,234.0 thousand in 2021, and the number is expected to reach 5,445.2 in 2030 and 7,464.0 in 2045. Such a high prevalence of diabetes in South Africa will lead to increased adoption of renal biomarker testing, as diabetes is a major contributor to renal diseases, thereby driving the market's growth.

List of Key and Emerging Players in Renal Biomarkers Market